Leading Brands

Brand building is at the core of our marketing strategy. A significant proportion of our revenues is derived from brands which are among top 10 in their respective subgroups. We derive a higher proportion of our revenues from our top 10 and top 25 mother brand groups, as compared to the average of the top 25 players in the IPM

  Top 10 Mother Brand Groups Revenue Contribution Top 25 Mother Brand Groups Revenue Contribution
Eris Lifesciences 76.0% 94.4%
Average of Top 25 Companies in IPM 49.9% 71.4%

Source: IMS TSA MAT, March 2016

Top Ten Brands

Brand Year of launch Indication Subgroup(including combinations) Sales Value in INR Millions Brand CAGR Market CAGR Prescription rank
Glimisave 2007 Anti – Diabetes Glimepiride 1526.6 29.7% 19.3% 3
Eritel 2008 Hypertension Telmisartan 993.1 36.7% 23.4% 4
Rabonik 2008 Gastroenterology Rabeprazole 572.7 15.0% 15.4% 10
Tayo 2011 Vit. D deficiency in Metabolic disorders Vitamin D 525.0 15.2% 27.0% 5
Remylin 2007 Diabetic Neuropathy Mecobalamin+Colecalciferol 520.7 12.1% 14.3% 6
Olmin 2010 Hypertension Olmesartan 447.4 45.3% 21.3% 3
Atorsave 2007 Lipid Lowering Atorvastatin 347.1 9.0% 4.1% 5
Lnbloc 2012 Hypertension Cilnidipine 315.2 > 100%* 88.5% 2
Crevast 2010 Lipid Lowering Rosuvastatin 203.1 21.5% 26.0% 5
Cyblex 2014 Anti – Diabetes Gliclazide 193.2 > 100%* 13.5% 6

Source: IMS TSA and Medical Audit MAT, Sep 2016
*4 year CAGR considered since brand launched post MAT Sep 2012